An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone who trains a lot and wants help with appetite wrote in saying tirzepatide (brand name Mounjaro) didn’t agree with them and they’re looking for other options to curb cravings without major digestive slowdown or big changes in calorie burn. They’re a full Ironman athlete training ~15 hours a week and want a drug that makes them feel “really w” — likely “really full” or “less driven to snack” — without wrecking training. The note is a personal question, not a clinical trial, so it’s about choices and trade-offs rather than a definitive new study. Tirzepatide (Mounjaro) is a prescription injectable medicine that acts on two gut-brain signaling systems that control hunger and blood sugar: GLP‑1 and GIP receptors. Those are proteins on cells that respond to hormones normally released after you eat. Drugs that activate these receptors (“agonists” — they turn the receptor on) can reduce appetite, help people eat less, and often slow how quickly the stomach empties, which can make you feel fuller longer. Semaglutide (Ozempic, Wegovy) acts mainly on GLP‑1 and does similar things. All these drugs are not simple appetite suppressants; they change the way your body signals hunger and fullness. Most of what we know about which drug causes which side effects comes from clinical trials and patient reports. Tirzepatide tends to be very effective at reducing appetite and body weight, but some people get nausea, stomach upset, or other GI (gastrointestinal) side effects that make training or daily life harder. Semaglutide has a fairly well-documented profile of reduced appetite and slowed digestion, plus similar GI side effects. Other options that people consider include lower-dose versions, different dosing schedules, or older medications with weaker appetite effects (like phentermine or bupropion), but those have different mechanisms, varying effectiveness, and their own side effects. Importantly, the snippet you shared is an individual asking for alternatives — it isn’t a study — so there’s no new evidence here about a superior option for athletes. Why it matters: endurance athletes and people who train a lot think differently about weight-loss drugs because they need consistent energy, fast recovery, and predictable GI function during long workouts and races. A medication that causes nausea or major stomach slow-down can wreck training and race performance, even if it helps reduce body fat. If appetite control is the main goal, some people try dose adjustments, switching between GLP‑1 drugs, or non-drug approaches like structured meal timing, higher-protein diets, behavioral strategies, or working with a sports dietitian. Those options may reduce cravings without risking GI trouble during hard training. Caveats and risks: these prescription drugs should be used under medical supervision. Side effects can include nausea, vomiting, diarrhea, and, rarely, more serious conditions like pancreatitis. They can interact with other medical conditions and medications. Stopping them often leads to weight regain unless lifestyle habits change. For athletes, there’s limited formal research on long-term effects of these drugs on performance and recovery, so individual responses vary. Over-the-counter supplements marketed for appetite suppression are poorly regulated and often ineffective or unsafe. Always talk to your doctor and, for athletes, a sports medicine specialist or dietitian before trying or switching medications. Bottom line: if tirzepatide didn’t suit you, there are alternatives and non-drug strategies to try, but each choice has trade-offs for appetite control versus GI side effects and training impact — discuss options with a clinician who knows endurance athletes.
Source: r/Semaglutide